2. Academic Validation
  3. The discovery of AZD9164, a novel muscarinic M3 antagonist

The discovery of AZD9164, a novel muscarinic M3 antagonist

  • Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6. doi: 10.1016/j.bmcl.2011.10.002.
Antonio Mete 1,  Keith Bowers,  Eric Chevalier,  David K Donald,  Helen Edwards,  Katherine J Escott,  Rhonan Ford,  Ken Grime,  Ian Millichip,  Barry Teobald,  Vince Russell
Affiliations

Affiliation

  • 1 Department of Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, UK. antonio.mete@astrazeneca.com
PMID: 22047691 DOI: 10.1016/j.bmcl.2011.10.002
Abstract

The optimization of a new series of muscarinic M(3) antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.

Figures
Products